AVXL Jan 2024 5.000 call

OPR - OPR Delayed price. Currency in USD
5.10
0.00 (0.00%)
As of 03:46PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close5.10
Open5.20
Bid0.00
Ask0.00
Strike5.00
Expiry date2024-01-19
Day's range5.10 - 5.20
Contract rangeN/A
Volume37
Open interestN/A
  • Zacks

    Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 342.31%: Here's is How to Trade

    The average of price targets set by Wall Street analysts indicates a potential upside of 342.3% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

  • GlobeNewswire

    Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results

    Newly available preliminary efficacy results of surrogate biomarkers from the ANAVEX®2-73-AD-004 study; allowing initiation of discussions with regulatory agencies for Accelerated Approval Pathway for ANAVEX®2-73 (blarcamesine) in Alzheimer’s disease with convenient oral treatment On track to release top-line data of potentially pivotal ANAVEX®2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial in the second half of 2023 Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, M

  • GlobeNewswire

    Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Results on Tuesday, May 9, 2023

    Webcast and Conference Call To be Held Tuesday, May 9, 2023, 8:30 am ETNEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial r

  • GlobeNewswire

    Anavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX®2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of Hypertension

    NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, announced today it was granted a new U.S. Patent No. 11,622,955 entitled “SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PR

  • GlobeNewswire

    Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

    NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participa

  • GlobeNewswire

    Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023

    NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other Central Nervous System (CNS) diseases, today announced that Christopher U Missling, PhD, President & Chief Executive Officer of Anavex will present at the

  • Zacks

    Here's Why You Should Add Acadia (ACAD) Stock to Your Portfolio

    Acadia (ACAD), a top-ranked stock at present, is witnessing steady growth in Nuplazid sales since its launch. The newly approved drug, Daybue, is set to provide an incremental stream of revenues.

  • Simply Wall St.

    When Can We Expect A Profit From Anavex Life Sciences Corp. (NASDAQ:AVXL)?

    Anavex Life Sciences Corp. ( NASDAQ:AVXL ) is possibly approaching a major achievement in its business, so we would...

  • GlobeNewswire

    ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson’s Disease Dementia

    ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson’s Disease Dementia ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson’s Disease Dementia Study successfully achieved both primary and secondary objectives ANAVEX®2-73 treatment resulted in improvements of all efficacy endpoints over 48 Weeks Anavex plans to proceed to ANAVEX®2-73 pivotal trial for Parkinso

  • Motley Fool

    Wall Street Thinks This Small-Cap Stock Can Quadruple in Value

    The company generates no revenue, but it may be worth taking a chance on as it possesses lots of upside.

  • Zacks

    Acadia (ACAD) Gets FDA Approval for Daybue for Rett Syndrome

    Acadia Therapeutics (ACAD) announces the FDA approval of its Rett Syndrome drug, trofinetide, for the treatment of adult and pediatric patients two years of age and older. Going to be marketed as Daybue in the United States.

  • GlobeNewswire

    Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as Vice President Head of Biostatistics

    NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Kun Jin, Ph.D., as Vice President, Head of Biostatistics. Dr. Jin will draw on h

  • Motley Fool

    Why Shares of Anavex Life Sciences Rose 12.4% in February

    Shares of Anavex Life Sciences (NASDAQ: AVXL) rose 12.4% in February, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech's stock closed at $10.87 in January, then rose to a high of $11.93 on Feb. 7, the day the company announced first-quarter earnings. The stock closed the month at $9.52.

  • Motley Fool

    Is Anavex Life Sciences Stock a Buy Now?

    A short squeeze could be a possibility if the company can prove that bearish investors are wrong about its business.

  • Zacks

    Does Anavex Life Sciences (AVXL) Have the Potential to Rally 270.28% as Wall Street Analysts Expect?

    The mean of analysts' price targets for Anavex Life Sciences (AVXL) points to a 270.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

  • Motley Fool

    This Short-Squeeze Candidate Could Actually Pan Out in the Long Run

    Secondly, and perhaps most importantly, Wall Street analysts -- at least those with a bullish view on the company -- think Anavex stock is massively undervalued right now. Anavex is a late-stage drugmaker with promising candidates in Alzheimer's disease, Parkinson's disease, Rett syndrome, and Schizophrenia, among others. Last December, blarcamesine reportedly hit the mark in a late-stage trial as an oral treatment for patients who have Alzheimer's disease.

  • Motley Fool

    Why Anavex Life Sciences Stock Bolted Higher in January

    The biotech's shares have been steadily leaking higher following positive late-stage Alzheimer's disease trial results.

  • GlobeNewswire

    Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results

    Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter en

  • GlobeNewswire

    Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

    NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the total enrollment of 92 patients with Rett syndrome for the ANAVEX®2-73 (blarcamesine) EXCELLENCE

  • GlobeNewswire

    Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on Tuesday February 7, 2023

    Webcast and Conference Call To be Held Tuesday, February 7, 2023, 8:30 am ETNEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue finan

  • Simply Wall St.

    We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

  • Zacks

    FDA Rejects Accelerated Nod to Lilly's (LLY) Alzheimer's Drug

    The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.

  • Motley Fool

    3 Biotech Stocks Under $15 Worth a Second Look in 2023

    Novavax stands out with its more traditional, protein-based COVID-19 vaccine; MannKind is making a name for itself with inhaled therapies for diabetics and patients with lung disorders; and Anavex has a promising Alzheimer's therapy.

  • Motley Fool

    Anavex Life Sciences Stock Could 5x Before 2025 -- Here's Why

    The biotech will first need to assuage the concerns of experts by elaborating on its latest clinical trial data.

  • GlobeNewswire

    Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial

    NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Prof. Dr. Timo Grimmer, MD, to its Scientific Advisory Board. Prof. Dr. Grimmer s